Our Projects

Lipigon is a project portfolio company currently managing three active drug projects, with Lipisense® being the most advanced.

  • Project 1 (P1): Lipisense®
    An RNA drug targeting elevated triglycerides.
  • Project 2 (P2): Lipodystrophi
    A gene therapy project for the rare disease lipodystrophy. Project in collaboration with Combigene AB (publ).
  • Project 3 (P3): Dyslipidemia
    A small molecule project for dyslipidemia (general lipid disorders). Project in partnership with HitGen, Inc.
  • Project 4 (P4): CAP
    An RNA drug project for Community-Acquired Pneumonia (CAP).

See the full pipeline